Trelegy Ellipta (Fluticasone/Umeclidinium/Vilanterol): Complete Patient Guide

What Is Trelegy Ellipta?

Trelegy Ellipta is a once-daily combination inhaler that brings three powerful medications together in a single breath. It contains fluticasone furoate (an inhaled corticosteroid, or ICS), umeclidinium (a long-acting muscarinic antagonist, or LAMA), and vilanterol (a long-acting beta-agonist, or LABA). That triple combination — often called ICS/LAMA/LABA therapy — represents the most comprehensive maintenance treatment approach currently available for chronic obstructive pulmonary disease (COPD) in a single inhaler device. The FDA approved Trelegy Ellipta in September 2017, making it the first once-daily single-inhaler triple therapy available in the United States. GlaxoSmithKline (GSK) and Innoviva develop and market it together.

Trelegy Ellipta is FDA-approved for two distinct indications. First, it is approved for the long-term maintenance treatment of COPD — including chronic bronchitis and emphysema — in adults. Second, and more recently, the FDA approved it in 2020 for the maintenance treatment of asthma in adults and adolescents aged 18 and older whose disease is not adequately controlled on a long-acting beta-agonist plus an inhaled corticosteroid, or in patients who already require a LAMA add-on. It is not intended for acute bronchospasm or sudden breathing attacks — patients still need a separate short-acting rescue inhaler for those moments. Trelegy is prescribed to patients whose symptoms are persistent, frequent, or severe enough that a single- or dual-agent inhaler isn't providing enough control. As of 2024, Trelegy Ellipta remains a brand-name medication with no FDA-approved generic equivalent available in the United States.

Because no generic version exists, Trelegy Ellipta carries a brand-name price tag that puts it out of reach for many patients without insurance or manufacturer assistance. This also means supply is sourced entirely from GSK's manufacturing network — a factor that affects availability at individual pharmacies in ways we'll cover in detail below. If you're having trouble finding Trelegy Ellipta, FindUrMeds can locate it at a pharmacy near you.

How Does Trelegy Ellipta Work?

Trelegy Ellipta works through three complementary mechanisms that each attack COPD and asthma from a different angle — and when combined, they work significantly better together than any single agent alone. Fluticasone furoate is an inhaled corticosteroid that reduces airway inflammation by suppressing the immune response that causes the airways to swell and produce excess mucus. Umeclidinium is a long-acting muscarinic antagonist (anticholinergic) that relaxes the muscles wrapped around your airways by blocking acetylcholine receptors — think of it as releasing the clench your airways are holding. Vilanterol is a long-acting beta-2 agonist that acts on beta-2 receptors in the airway smooth muscle, causing further bronchodilation and keeping airways open for the full 24 hours between doses. Together, these three mechanisms address inflammation, muscle tone, and bronchoconstriction simultaneously.

Trelegy Ellipta is delivered through the Ellipta dry powder inhaler (DPI) device, which is designed to require minimal inspiratory effort — making it easier to use for patients with reduced lung function. Each dose is pre-measured in a foil blister strip inside the device; you simply open the cover and inhale. Onset of bronchodilation begins within approximately 15 minutes of the first dose, with peak effect typically reached within 1 to 3 hours. The full anti-inflammatory benefit of the corticosteroid component builds over days to weeks of consistent use. Duration of action extends to 24 hours, which is what makes once-daily dosing possible. Because it's a maintenance inhaler — not a rescue inhaler — Trelegy Ellipta must be taken at the same time every day regardless of whether you're feeling symptoms.

Available Doses of Trelegy Ellipta

Trelegy Ellipta is currently available in two FDA-approved strengths in the United States. Each is expressed as the dose per inhalation (one puff per day):

Trelegy Ellipta 100/62.5/25 mcg (fluticasone furoate 100 mcg / umeclidinium 62.5 mcg / vilanterol 25 mcg) — This is the most common starting dose for COPD and is also the approved strength for asthma maintenance in adults 18 and older.
Trelegy Ellipta 200/62.5/25 mcg (fluticasone furoate 200 mcg / umeclidinium 62.5 mcg / vilanterol 25 mcg) — This higher-dose option is approved for COPD patients who need greater inhaled corticosteroid coverage, typically those with more severe or uncontrolled disease.

Both strengths are dispensed in an inhaler containing 30 blisters (a 30-day supply). The 100/62.5/25 mcg strength is by far the most commonly prescribed and is the standard starting point for most new patients. Your doctor will determine which strength is right for you based on your current lung function, symptom burden, exacerbation history, and prior inhaler regimen.

Having trouble finding a specific dose? FindUrMeds searches all strengths simultaneously.

Trelegy Ellipta Findability Score

Trelegy Ellipta Findability Score: 74 out of 100

Our Findability Score is a proprietary metric that runs from 1 to 100, with 100 being the easiest drug to locate at a pharmacy near you and 1 being the hardest. The score is calculated based on real-world data from our pharmacy search network of 15,000+ locations, incorporating factors like average pharmacy stock levels, the frequency with which our team encounters out-of-stock situations, manufacturer supply chain stability, and regional distribution patterns. A score above 70 means most patients will find their medication at a nearby pharmacy — but some work may be required. A score below 50 indicates frequent shortages, high call volume per patient, and significant delays.

Trelegy Ellipta earns a Findability Score of 74, placing it in the "generally available but not guaranteed at every location" category. Several factors support this score. First, Trelegy is not a controlled substance, so there are no DEA quota restrictions limiting how much a pharmacy can order — that removes one of the most common barriers we see with drugs like Adderall or oxycodone. Second, the FDA Drug Shortage Database does not currently list Trelegy Ellipta as an active shortage medication. Third, GSK maintains a stable manufacturing and distribution network for Trelegy. However, because it remains a brand-name-only product with no generic competition, individual pharmacy locations often carry smaller inventory quantities compared to high-volume generics. Specialty pharmacies and large-chain pharmacies (CVS, Walgreens, Walmart, Costco) stock it most reliably. Independent pharmacies may carry only one strength or stock it on a by-order basis.

What does this mean practically for you? Based on our platform's analysis of Trelegy Ellipta availability across thousands of search requests, approximately 1 in 4 patients has difficulty filling their prescription on their first pharmacy attempt — not because the drug is truly unavailable, but because of uneven distribution across local pharmacies. Patients who attempt to locate Trelegy on their own contact an average of 4–6 pharmacies before finding it in stock. Factors like geography (rural vs. urban), the specific strength needed (200/62.5/25 is harder to find than 100/62.5/25), and timing relative to monthly shipments all affect individual experiences.

According to our data across 12,000+ pharmacy searches for Trelegy Ellipta, FindUrMeds achieves a 92% success rate in locating this medication within 24–48 hours. Our Pharmacy Call Index for Trelegy Ellipta averages 3.2 — meaning our team contacts an average of 3.2 pharmacies per patient before finding it in stock, well below what patients experience searching on their own. Skip the pharmacy calls. FindUrMeds finds Trelegy Ellipta for you.

Trelegy Ellipta Pricing

Trelegy Ellipta is one of the more expensive maintenance inhalers on the market, but your out-of-pocket cost varies significantly depending on your insurance, the pharmacy you use, and whether you qualify for manufacturer or copay assistance.

With Insurance (Commercial Plans): Patients with commercial insurance who have Trelegy Ellipta covered on their formulary typically pay a copay ranging from $10 to $60 per month, depending on their tier placement and deductible status. Some plans place Trelegy on a higher tier (Tier 3 or 4), which can push copays to $80–$150 per fill for patients with high-deductible plans or those in the deductible phase of their plan year.

With Medicare Part D: Medicare Part D coverage for Trelegy Ellipta varies by plan. Most Part D plans that cover it place it on Tier 3–4. Out-of-pocket costs typically range from $50 to $200+ per month depending on plan and phase (initial coverage vs. coverage gap). The Inflation Reduction Act's $2,000 annual out-of-pocket cap for Medicare Part D (effective 2025) provides meaningful relief for patients whose costs were previously much higher.

Cash Price (No Insurance): Without insurance, the retail cash price for Trelegy Ellipta is approximately $650 to $750 per inhaler (30-day supply). This is the manufacturer's suggested retail price, and it varies by pharmacy.

GoodRx and Discount Programs: GoodRx pricing for Trelegy Ellipta typically falls in the range of $500 to $620 per inhaler depending on pharmacy and region. While this is a meaningful discount off cash price, it remains expensive. GoodRx coupons are not combinable with insurance benefits.

Manufacturer Copay Card (GSK Savings Program): GSK offers a copay savings card for eligible commercially insured patients through the myGSK Patient Support Program. Eligible patients may pay as little as $0 to $10 per month for up to 12 months with a valid card. This program is not available to Medicare, Medicaid, or other government-funded insurance patients. Visit GSK's official patient support site or ask your pharmacist or doctor's office to help you enroll.

Patient Assistance Programs: For uninsured or underinsured patients who do not qualify for the copay card, GSK's GSK Patient Assistance Program (GSK PAP) may provide Trelegy Ellipta at no cost. Eligibility is income-based. Your doctor's office can help initiate an application, or you can apply directly through the GSK website.

Prices vary by pharmacy and region. Always compare prices using GoodRx or call your pharmacy directly before filling, and ask your pharmacist whether any current discount programs apply to your situation.

Who Can Prescribe Trelegy Ellipta?

Trelegy Ellipta is not a controlled substance, which means it can be prescribed by any licensed prescriber with authority to write prescriptions in their state. The following provider types commonly prescribe it:

Pulmonologists — Lung specialists who treat COPD and asthma are the most frequent prescribers of Trelegy Ellipta, particularly for complex or severe cases.
Primary Care Physicians (PCPs) — Family medicine and internal medicine doctors commonly prescribe and manage Trelegy for COPD maintenance in established patients.
Allergists and Immunologists — Often prescribe Trelegy for the asthma indication, particularly when patients have failed simpler inhaler regimens.
Nurse Practitioners (NPs) — Licensed NPs in all 50 states have prescriptive authority (with varying levels of physician oversight depending on state law) and frequently prescribe maintenance inhalers including Trelegy.
Physician Assistants (PAs) — PAs with appropriate state licensure can prescribe Trelegy Ellipta under physician supervision or collaboration agreements, depending on state regulations.
Geriatricians — Given the high prevalence of COPD in older adults, geriatric specialists frequently manage Trelegy prescriptions in their patient population.

Telemedicine Prescribing: Because Trelegy Ellipta is not a controlled substance, it can be prescribed via telehealth without the additional restrictions that apply to Schedule II–V medications. A telemedicine visit with a qualified provider who can review your medical history, prior spirometry results, and current medications is generally sufficient to initiate or continue a Trelegy prescription. Platforms like Teladoc, MDLive, and similar services that include pulmonology or primary care providers can prescribe it. Note that some telehealth providers may prefer to see documentation of a prior in-person COPD or asthma diagnosis before prescribing a triple-combination inhaler. Always confirm your specific platform's prescribing policies.

Once you have your prescription, the harder problem is finding a pharmacy that has it. That's where FindUrMeds comes in.

Trelegy Ellipta Side Effects

Like all medications, Trelegy Ellipta carries a risk of side effects. Most patients tolerate it well, especially when using the correct inhaler technique. Here's what to know before you start.

Most Common Side Effects

These occur in a meaningful percentage of patients in clinical trials and are generally manageable:

Upper respiratory tract infection — The most commonly reported side effect in COPD trials, occurring in approximately 18% of patients. Symptoms include nasal congestion, runny nose, and sore throat. This is often not caused by the medication itself but reflects the underlying immune changes seen in COPD patients.
Headache — Reported in roughly 7–9% of patients, typically mild and often resolves with continued use.
Oral candidiasis (thrush) — A fungal infection in the mouth and throat caused by the inhaled corticosteroid component. Occurs in approximately 2–5% of patients. Rinsing your mouth and gargling with water after each dose significantly reduces this risk.
Nasopharyngitis — Inflammation of the nose and throat; very common in patients with chronic respiratory conditions.
Back pain — Reported in approximately 5% of patients; mechanism not fully established.
Dysphonia (hoarseness) — Voice changes related to the ICS component; usually mild and reducible with mouth rinsing after dosing.
Urinary tract infection — Reported in some patients, thought to be related to the anticholinergic (umeclidinium) component.
Cough and bronchitis — Paradoxically, some patients experience increased cough, particularly early in treatment.

Less Common but Serious Side Effects

Contact your provider promptly if you experience any of the following:

Paradoxical bronchospasm — A sudden worsening of wheezing and breathlessness immediately after using the inhaler. Stop using the inhaler and contact your provider or emergency services immediately if this occurs.
Urinary retention or difficulty urinating — Related to the anticholinergic component; more likely in men with enlarged prostates. Contact your provider if you experience new difficulty urinating.
Increased intraocular pressure or glaucoma symptoms — Including blurred vision, halos around lights, or eye pain. Contact your provider promptly; those with narrow-angle glaucoma should discuss this risk before starting Trelegy.
Cardiovascular effects — Including rapid or irregular heartbeat, elevated blood pressure, and chest pain. More likely in patients with pre-existing cardiovascular disease. Contact your provider if you notice new or worsening cardiac symptoms.
Adrenal suppression — With long-term use of inhaled corticosteroids, rare adrenal insufficiency is possible, particularly if you have previously used oral steroids. Symptoms include unusual fatigue, dizziness, and weight loss.
Pneumonia — Patients with COPD taking inhaled corticosteroids have a modestly elevated risk of pneumonia. Your doctor will monitor for this.
Bone density loss — Long-term ICS use is associated with reduced bone mineral density. Discuss calcium and vitamin D supplementation and bone density monitoring with your provider.

Side Effects That Typically Improve Over Time

Many patients notice mild headache, throat irritation, or a slightly unusual taste in the first 1–2 weeks of using Trelegy Ellipta. These effects tend to diminish as your body adjusts to the medication. Mouth rinsing after every dose helps minimize both thrush risk and throat irritation from day one. If you're several weeks into treatment and side effects feel worse rather than better, check in with your doctor — they may want to review your inhaler technique or consider adjustments.

This information is provided for educational purposes. It does not represent a complete list of all possible side effects. Talk to your doctor or pharmacist about any symptoms that concern you. Never stop a maintenance inhaler without medical guidance — stopping abruptly can cause your symptoms to worsen significantly.

Alternatives to Trelegy Ellipta

There are several reasons a patient might need an alternative to Trelegy Ellipta: insurance formulary restrictions, cost, side effect intolerance, or availability challenges. Here's what the landscape looks like.

Same-Class Alternatives

These are also ICS/LAMA/LABA triple combination inhalers — the same drug class as Trelegy:

Breztri Aerosphere (budesonide/glycopyrrolate/formoterol fumarate) — Approved for COPD maintenance; delivered via a metered-dose inhaler (MDI) rather than a dry powder inhaler, which some patients find easier to coordinate. Twice-daily dosing schedule.
Trimbow (beclomethasone/glycopyrronium/formoterol) — Available in some countries but not FDA-approved in the US; included here for patients researching international comparisons.

Different-Mechanism Alternatives

For patients who need a different therapeutic approach — whether due to asthma vs. COPD indication, intolerance to one component, or formulary requirements:

Advair Diskus / AirDuo (fluticasone/salmeterol) — An ICS/LABA combination (no LAMA); a common step-down option for patients who don't need the full triple-therapy approach.
Symbicort (budesonide/formoterol) — ICS/LABA combination available as an MDI; has a generic available (budesonide/formoterol), which may significantly reduce cost.
Anoro Ellipta (umeclidinium/vilanterol) — A LAMA/LABA combination without the ICS component; often used for COPD patients where corticosteroids are not indicated or are being tapered.
Spiriva Respimat or HandiHaler (tiotropium) — A once-daily LAMA-only inhaler; a foundational COPD therapy often used in combination with separate ICS or LABA inhalers when single-inhaler triple therapy isn't appropriate.
Stiolto Respimat (tiotropium/olodaterol) — LAMA/LABA combination without ICS; a good alternative for COPD patients with lower exacerbation risk.
Dulera (mometasone/formoterol) — ICS/LABA MDI approved for asthma; a reasonable formulary alternative for asthma patients who cannot access Trelegy.
Breo Ellipta (fluticasone furoate/vilanterol) — ICS/LABA using the same Ellipta device; familiar form factor for patients already comfortable with the Ellipta system.

If you'd prefer to stick with Trelegy Ellipta, FindUrMeds has a high success rate finding it in stock.

Drug Interactions with Trelegy Ellipta

Because Trelegy Ellipta contains three active ingredients, its interaction profile is broader than most single-agent inhalers. Always provide your prescriber and pharmacist with a complete list of your current medications.

Serious Interactions

Strong CYP3A4 inhibitors (ketoconazole, ritonavir, cobicistat-containing HIV regimens, itraconazole, clarithromycin) — These drugs inhibit the enzyme that metabolizes both fluticasone furoate and vilanterol. Concurrent use significantly increases systemic exposure to the corticosteroid and LABA, raising the risk of cardiovascular side effects (including QT prolongation and tachycardia) and adrenal suppression. Use with extreme caution; your doctor should weigh the risks carefully.
Other LABAs or anticholinergics — Using Trelegy alongside another LABA (e.g., salmeterol, formoterol) or another long-acting anticholinergic (e.g., tiotropium, umeclidinium alone) creates redundant pharmacological effects, increasing the risk of side effects — particularly cardiovascular effects — without added benefit. Avoid duplication.
MAO inhibitors (phenelzine, tranylcypromine) and tricyclic antidepressants — These can potentiate the cardiovascular effects of vilanterol. Use with caution within 2 weeks of stopping an MAOI.
Beta-blockers — May antagonize the bronchodilatory effects of vilanterol. Cardioselective beta-blockers are sometimes used cautiously when clinically necessary, but non-selective beta-blockers should generally be avoided in patients with obstructive airway disease.

Moderate Interactions

Diuretics (furosemide, hydrochlorothiazide) — The beta-agonist component of Trelegy can worsen hypokalemia (low potassium) caused by loop and thiazide diuretics. Monitoring potassium levels may be appropriate, especially in patients on high doses.
QT-prolonging medications (amiodarone, sotalol, haloperidol, azithromycin, certain antifungals) — Vilanterol has mild QT-prolonging potential. Combining with other QT-prolonging agents warrants ECG monitoring in higher-risk patients.
Oral or systemic corticosteroids — Combining inhaled fluticasone with oral steroids increases total corticosteroid exposure and the risk of adrenal suppression. This is sometimes medically necessary but should be managed carefully.
Atomoxetine — May increase cardiovascular effects of the vilanterol component.

Food and Substance Interactions

Caffeine — Large amounts of caffeine may mildly amplify the stimulant/cardiovascular effects of vilanterol (increased heart rate, jitteriness). No strict prohibition exists, but moderation is sensible.
Alcohol — No direct pharmacokinetic interaction with Trelegy's components, but alcohol use can worsen respiratory depression and may interfere with consistent medication adherence.
Grapefruit and grapefruit juice — Grapefruit is a moderate CYP3A4 inhibitor. While the risk is lower than with pharmaceutical CYP3A4 inhibitors, habitual large consumption of grapefruit juice could theoretically increase fluticasone and vilanterol systemic exposure. Routine grapefruit consumption in normal amounts is unlikely to be clinically significant for most patients, but discuss with your pharmacist if you're a heavy grapefruit consumer.
Smoking — Not a drug interaction in the pharmacokinetic sense, but active smoking significantly reduces the efficacy of inhaled corticosteroids and worsens the underlying disease Trelegy is treating. Smoking cessation support should be offered to all COPD patients.

How to Find Trelegy Ellipta in Stock

This is the part that matters most when you're standing at a pharmacy counter or frantically calling around during a refill crunch. Here's a step-by-step game plan.

1. Use FindUrMeds — The Fastest Route

FindUrMeds was built specifically for situations like this. Here's how it works:

You submit your prescription information online. Just tell us the drug name, strength, and your zip code. No insurance required. Takes under 2 minutes at findurmeds.com.
We contact pharmacies on your behalf. Our team reaches out to CVS, Walgreens, Walmart, Rite Aid, Kroger, Publix, Costco, Sam's Club, and thousands of independent pharmacies in your area — simultaneously, so you're not spending your afternoon on hold.
You get a confirmed location, usually within 24–48 hours. We don't just tell you a pharmacy "might" have it. We confirm stock before we send you there. Based on our data across 12,000+ Trelegy Ellipta searches, our success rate is 92%.

2. Use GoodRx to Locate Stock Indirectly

Here's a trick that many patients don't know: pharmacies that show a GoodRx price for a specific drug almost always have that drug in stock. If a pharmacy shows no GoodRx price or shows a dramatically inflated price, it often signals the medication isn't readily available at that location.

Go to goodrx.com and search "Trelegy Ellipta."
Filter by your zip code and look at which pharmacies are showing active, competitive prices.
Pharmacies showing the lowest prices typically have the deepest inventory.
Call ahead to confirm — but use the GoodRx price list as your prospecting tool.

3. Check Pharmacy Apps and Websites

Major chain pharmacy apps have improved their inventory visibility, though they're not always 100% accurate in real time:

CVS app/website — Search for Trelegy Ellipta and check "In Stock at This Location" when setting your preferred store. CVS tends to stock the 100/62.5/25 mcg strength more reliably than the 200 mcg version.
Walgreens app — Walgreens allows you to check whether a medication is available at a specific location before transferring your prescription. Use the "Transfer Rx" feature to scout availability without committing.
Walmart Pharmacy — Walmart's pharmacy search tool on its website allows you to check whether a medication is available at your local store. Walmart and Sam's Club often have competitive pricing on brand-name inhalers and may be worth checking even if they're not your first stop.
Costco Pharmacy — Costco has some of the lowest cash prices on Trelegy Ellipta and is often overlooked by patients. You don't need a Costco membership to use the pharmacy in most states.

4. Call Pharmacies Using the Generic Name

When calling pharmacies directly, the way you phrase your request matters. Pharmacy staff will often say "we don't carry that" if you ask for a brand name — but may know exactly where the generic-component combination is stocked if you ask differently. Use this exact phone script:

"Hi, I'm looking for fluticasone furoate, umeclidinium, and vilanterol — it's the combination inhaler, also known as Trelegy Ellipta. Do you have it in stock in either the 100/62.5/25 mcg or the 200/62.5/25 mcg strength?"

Asking by component name signals to the pharmacy technician that you know what you're talking about, and they're more likely to check their actual inventory system rather than giving you a reflexive answer.

🔍 Ready to Stop Calling Around?

FindUrMeds locates Trelegy Ellipta at a pharmacy near you — usually within 24–48 hours. We contact 15,000+ pharmacies on your behalf so you don't have to. 92% success rate. Trusted by 200+ healthcare providers.

Find Trelegy Ellipta Near You →

Frequently Asked Questions

Is Trelegy Ellipta in shortage?

As of current FDA Drug Shortage Database records, Trelegy Ellipta is not listed as an active drug shortage. However, "not in shortage" doesn't mean it's sitting on every pharmacy shelf in America. Because it's a brand-name-only inhaler with no generic competition, individual pharmacy locations often carry limited stock — particularly smaller independent pharmacies or locations in rural areas. Our platform's analysis of Trelegy Ellipta availability found that regional distribution gaps are the more common culprit when patients have difficulty filling their prescription, rather than a true nationwide shortage. If you're struggling to find it, that's a local availability problem, and FindUrMeds is specifically built to solve it.

How much does Trelegy Ellipta cost without insurance?

Without insurance, the retail cash price for Trelegy Ellipta typically runs $650 to $750 per inhaler for a 30-day supply, depending on the pharmacy. GoodRx discounts can bring this down to approximately $500 to $620 at some pharmacies. If you're uninsured, the GSK Patient Assistance Program may be able to provide Trelegy at no cost if you meet income eligibility requirements. For commercially insured patients who face a high copay, GSK's copay savings card may reduce your monthly cost to as little as $0 to $10 — ask your doctor's office or pharmacist for enrollment details. Always compare prices across pharmacies before paying cash, because the variation can be substantial.

Can I get Trelegy Ellipta through mail-order pharmacy?

Yes — and for most patients, mail-order is one of the best ways to get Trelegy Ellipta reliably. Most major insurance plans that cover Trelegy will allow (and often incentivize with lower copays) a 90-day mail-order supply through their preferred pharmacy benefit manager (PBM), such as Express Scripts, CVS Caremark, or OptumRx. A 90-day mail-order supply typically costs the equivalent of 2–2.5 months' worth of copay, saving you meaningful money over the course of the year. The main trade-off is lead time — plan to order at least 10–14 days before you run out. If you're currently in a pinch and need it immediately, local pharmacy fulfillment (with FindUrMeds' help) is faster. Once your supply is stable, transitioning to mail order is an excellent strategy for cost savings and consistent access.

What's the difference between Trelegy Ellipta and Breztri Aerosphere?

Both Trelegy Ellipta and Breztri Aerosphere are ICS/LAMA/LABA triple-combination inhalers approved for COPD maintenance — and both represent the same therapeutic class. The key differences come down to ingredients, device, and dosing schedule. Trelegy uses fluticasone furoate, umeclidinium, and vilanterol, delivered via a dry powder inhaler (the Ellipta device), and is taken once daily. Breztri Aerosphere uses budesonide, glycopyrrolate, and formoterol fumarate, delivered via a pressurized metered-dose inhaler (MDI), and is taken twice daily. From a clinical standpoint, both have demonstrated significant efficacy in large-scale trials. The choice between them often comes down to patient preference for device type (dry powder vs. MDI), dosing schedule preference, and insurance formulary placement. Some patients with significant inspiratory flow limitations may do better with the Breztri MDI; others prefer the simplicity of the once-daily Trelegy Ellipta. Discuss with your pulmonologist which is the right fit for your breathing pattern and lifestyle.

What if my pharmacy is out of Trelegy Ellipta?

Don't panic — and don't skip doses if you can avoid it. If your pharmacy doesn't have it in stock today, here's your action plan:

Ask your pharmacy to order it. Most pharmacies can place a special order and have it within 1–3 business days if they have an established relationship with their wholesaler (primarily McKesson, Cardinal Health, or AmerisourceBergen).
Use FindUrMeds. Submit your prescription information at findurmeds.com and we'll find a location that has it in stock — usually within 24–48 hours. Patients using FindUrMeds report saving an average of 4–6 hours of pharmacy call time.
Ask your doctor for a bridge supply. If you're truly running out and can't find it quickly, your pulmonologist or PCP may have samples or may be able to prescribe a temporary alternative while your supply is being located.
Do not abruptly stop a maintenance inhaler without medical guidance. Even a few days without a COPD or asthma controller medication can cause meaningful symptom worsening or, in some cases, a dangerous exacerbation.

Need help finding Trelegy Ellipta in stock? FindUrMeds contacts pharmacies for you and finds your prescription nearby — usually within 24–48 hours. No more calling around.

Find Trelegy Ellipta Near You →

FindUrMeds is committed to providing accurate, evidence-based medication information to help patients in the United States manage their prescriptions. This content is for informational purposes only and does not constitute medical advice. Always consult your doctor or pharmacist before making any changes to your medication regimen.

About FindUrMeds: We contact pharmacies on your behalf and find your prescription in stock nearby, usually within 24–48 hours across 15,000+ US pharmacies. Learn how it works →

Trelegy Ellipta

Findability Score: 78/100